Literature DB >> 3355362

Embryotoxic effects of thalidomide-derivatives in the non-human primate Callithrix jacchus. I. Effects of 3-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-dioxopiperidine (EM12) on skeletal development.

H J Merker1, W Heger, K Sames, H Stürje, D Neubert.   

Abstract

The response of pregnant marmosets (Callithrix jacchus) to the thalidomide derivative EM 12 was evaluated. EM 12 was selected for these studies because it is more active than thalidomide and is much more stable for hydrolysis. Skeletal gross structural abnormalities were observed when EM 12 was given to marmosets for 3-7 days during the period between days 49 and 60 post ovulation. Using the treatment schedule finally adapted in our laboratory, i.e. treatment during days 51-57 post ovulation, doses of 5 (or 10) mg EM 12/kg body wt induced the typical limb abnormalities known from man with an 80-100% certainty. In some animals we could observe the typical pattern of abnormalities even with doses as low as 1 mg EM 12/kg body wt. Abnormalities of the skeleton induced during this sensitive period are described. None of these (except some bifurcations of ribs) were seen in any of the ten litters (23 fetuses) serving as controls during the period of the study.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3355362     DOI: 10.1007/bf00316631

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  37 in total

1.  Thalidomide and congenital abnormalities.

Authors:  G S SOMERS
Journal:  Lancet       Date:  1962-04-28       Impact factor: 79.321

2.  Thalidomide embryopathy.

Authors:  W LENZ; K KNAPP
Journal:  Arch Environ Health       Date:  1962-08

3.  [On the problem of exogenous causes of severe malformations of the extremities].

Authors:  R A PFEIFFER; W KOSENOW
Journal:  Munch Med Wochenschr       Date:  1962-01-12

4.  The effect of thalidomide intake during 113 human pregnancies.

Authors:  T Kajii; M Kida; K Takahashi
Journal:  Teratology       Date:  1973-10

5.  Normal and abnormal development of human embryos: first report of the analysis of 1,213 intact embryos.

Authors:  H Nishimura; K Takano; T Tanimura; M Yasuda
Journal:  Teratology       Date:  1968-08

6.  [Dysplasia in the mouth, jaw and teeth in dysmelia. Contribution to the thalidomide-embryopathies].

Authors:  A Stahl
Journal:  Dtsch Zahnarztl Z       Date:  1967-02

Review 7.  Principles and problems in assessing prenatal toxicity.

Authors:  D Neubert; I Chahoud; T Platzek; R Meister
Journal:  Arch Toxicol       Date:  1987       Impact factor: 5.153

8.  The sensitive period and malformation syndrome produced by thalidomide in crab-eating monkey (Macaca fascicularis).

Authors:  A G Hendrickx
Journal:  J Med Primatol       Date:  1973       Impact factor: 0.667

9.  Determination of ovulation and pregnancy in the marmoset (Callithrix jacchus) by monitoring of urinary hydroxypregnanolone excretion.

Authors:  W Heger; D Neubert
Journal:  J Med Primatol       Date:  1987       Impact factor: 0.667

10.  Timing of ovulation and implantation in the common marmoset, Callithrix jacchus, by monitoring of estrogens and 6 beta-hydroxypregnanolone in urine.

Authors:  H W Heger; D Neubert
Journal:  Arch Toxicol       Date:  1983-09       Impact factor: 5.153

View more
  14 in total

1.  Embryotoxic effects of thalidomide derivatives in the non-human primate Callithrix jacchus. II. Elucidation of the susceptible period and of the variability of embryonic stages.

Authors:  D Neubert; W Heger; H J Merker; K Sames; R Meister
Journal:  Arch Toxicol       Date:  1988-01       Impact factor: 5.153

2.  Embryotoxic effects of thalidomide derivatives on the non-human primate Callithrix jacchus; 3. Teratogenic potency of the EM 12 enantiomers.

Authors:  W Heger; S Klug; H J Schmahl; H Nau; H J Merker; D Neubert
Journal:  Arch Toxicol       Date:  1988       Impact factor: 5.153

3.  Transfer of various polychlorinated dibenzo-p-dioxins and dibenzofurans (PCDDs and PCDFs) via placenta and through milk in a marmoset monkey.

Authors:  H Hagenmaier; T Wiesmüller; G Golor; R Krowke; H Helge; D Neubert
Journal:  Arch Toxicol       Date:  1990       Impact factor: 5.153

4.  Persistence of various polychlorinated dibenzo-p-dioxins and dibenzofurans (PCDDs and PCDFs) in hepatic and adipose tissue of marmoset monkeys.

Authors:  D Neubert; T Wiesmüller; K Abraham; R Krowke; H Hagenmaier
Journal:  Arch Toxicol       Date:  1990       Impact factor: 5.153

Review 5.  Thalidomide-type teratogenicity: structure-activity relationships for congeners.

Authors:  R L Smith; S C Mitchell
Journal:  Toxicol Res (Camb)       Date:  2018-09-26       Impact factor: 3.524

Review 6.  Thalidomide in human immunodeficiency virus (HIV) patients. A review of safety considerations.

Authors:  V Günzler
Journal:  Drug Saf       Date:  1992 Mar-Apr       Impact factor: 5.606

Review 7.  Understanding developmental mechanisms in the context of osteoarthritis.

Authors:  Peter M van der Kraan
Journal:  Curr Rheumatol Rep       Date:  2013-06       Impact factor: 4.592

8.  Thalidomide derivatives and the immune system. I. Changes in the pattern of integrin receptors and other surface markers on T lymphocyte subpopulations of marmoset blood.

Authors:  R Neubert; A C Nogueira; D Neubert
Journal:  Arch Toxicol       Date:  1993       Impact factor: 5.153

9.  Embryotoxic effects of thalidomide derivatives in the non-human primate Callithrix jacchus. 5. Lack of teratogenic effects of phthalimidophthalmide.

Authors:  S Klug; A Felies; H Stürje; A C Nogueira; R Neubert; E Frankus
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

10.  Comparative Genomics Identifies Putative Interspecies Mechanisms Underlying Crbn-Sall4-Linked Thalidomide Embryopathy.

Authors:  Thayne Woycinck Kowalski; Gabriela Barreto Caldas-Garcia; Julia do Amaral Gomes; Lucas Rosa Fraga; Lavínia Schuler-Faccini; Mariana Recamonde-Mendoza; Vanessa Rodrigues Paixão-Côrtes; Fernanda Sales Luiz Vianna
Journal:  Front Genet       Date:  2021-06-23       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.